Biopharmaceutical company Sermonix Pharmaceuticals announced on Monday a strategic collaboration with Regor Therapeutics Group, a clinical-stage biotechnology company, to optimise Regor's rCARD (Regor Computer Accelerated Rational Discovery) platform for identification of novel targets and therapeutics to fulfil unmet patient clinical needs and preferences in the breast oncology arena.

This partnership brings together the key core competencies of both companies to leverage expertise from early discovery to preclinical, clinical and commercial launch.

The aim is to develop effective treatments for advanced metastatic breast cancer, with tolerability and quality of life profiles that are aligned with patient priorities and concerns.

Dr David Portman, Sermonix founder and CEO, said: "Regor's translational to clinical approach -- and then confirmation of clinical impact -- is one we greatly admire and is producing molecules for development that will be best in class from both an efficacy and tolerability perspective.

"Deep patient insights and the potential to develop targets that can ultimately provide efficacy while addressing areas of key concerns to patients such as vaginal, bone and cardiovascular health would be fulfilling on the promise of optimised drug development."